Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 684 results for kidney or kidneys or renal

  1. Frequency of review: What is the most clinical and cost-effective frequency of review for children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  2. Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of renin–angiotensin–aldosterone system (RAAS) antagonists? [2014]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  3. Treatment of ESA resistance in people on haemodialysis: What is the most effective type of intervention to treat people on haemodialysis with ESA‑resistant anaemia?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  4. Risk assessment, referral criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  5. Investigations for proteinuria: In children and young people, what is the accuracy of reagent strips for detecting albumin in urine?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  6. Managing anaemia: What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  7. Self-management of CKD: Does the provision of educational and supportive interventions to people with CKD by healthcare professionals increase the person's skills and confidence in managing their conditions and improve clinical outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  8. Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  9. Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  10. Phosphate binders: Which binders are the most clinically and cost effective in controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  11. Investigations for proteinuria: What is the effect of measuring proteinuria with albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with CKD? [2021]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  12. Managing anaemia: For adults, children and young people with CKD and anaemia, what is the diagnostic accuracy of eGFR thresholds of 60, 45, and 30 ml/min/1.73 m2 for determining whether the anaemia is due to CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  13. Managing anaemia: For adults, children and young people with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  14. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  15. Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what is the clinical and cost effectiveness and safety of long-term calcium acetate combined with magnesium carbonate for controlling serum phosphate?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021